Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis
Abstract Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-01-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-023-00636-z |
| _version_ | 1797266657818705920 |
|---|---|
| author | Han Xie Yuan Zhang Zunyi Zhu Jingxuan Wei Gulinigeer Ainiwaer Weihong Ge |
| author_facet | Han Xie Yuan Zhang Zunyi Zhu Jingxuan Wei Gulinigeer Ainiwaer Weihong Ge |
| author_sort | Han Xie |
| collection | DOAJ |
| description | Abstract Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib efficacy in OA for personalized therapy optimization. Methods From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed proteins (DEPs) were validated using enzyme-linked immunosorbent assays (ELISA). Results Sixty-six patients with knee OA were included and divided into responders (n = 35) and non-responders (n = 31). Proteomic analysis was conducted on 15 patients from each group, with ELISA validation for every patient. We found 140 DEPs between the two groups after imrecoxib treatment, characterized by 29 proteins showing upregulation and 111 displaying downregulation (P < 0.05, fold change > ± 1.2). Galectin-1 (LGALS1), galectin-3 (LGALS3), and cluster of differentiation 44 (CD44) were identified as potential markers for evaluating clinical response to imrecoxib in OA following ELISA validation. Conclusion This study successfully identified biomarkers for evaluating imrecoxib’s clinical response in patients with OA using 4D-DIA technology. These biomarkers may play a vital role in future personalized OA treatment strategies, pending further confirmation. |
| first_indexed | 2024-04-25T01:04:11Z |
| format | Article |
| id | doaj.art-be7262228e4b46a6969ff32418a52e21 |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-04-25T01:04:11Z |
| publishDate | 2024-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-be7262228e4b46a6969ff32418a52e212024-03-10T12:21:55ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842024-01-0111226928310.1007/s40744-023-00636-zPlasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of OsteoarthritisHan Xie0Yuan Zhang1Zunyi Zhu2Jingxuan Wei3Gulinigeer Ainiwaer4Weihong Ge5Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Pharmacy, China Pharmaceutical University Nanjing Drum Tower HospitalDepartment of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical UniversityDepartment of Pharmacy, China Pharmaceutical University Nanjing Drum Tower HospitalDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityAbstract Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib efficacy in OA for personalized therapy optimization. Methods From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed proteins (DEPs) were validated using enzyme-linked immunosorbent assays (ELISA). Results Sixty-six patients with knee OA were included and divided into responders (n = 35) and non-responders (n = 31). Proteomic analysis was conducted on 15 patients from each group, with ELISA validation for every patient. We found 140 DEPs between the two groups after imrecoxib treatment, characterized by 29 proteins showing upregulation and 111 displaying downregulation (P < 0.05, fold change > ± 1.2). Galectin-1 (LGALS1), galectin-3 (LGALS3), and cluster of differentiation 44 (CD44) were identified as potential markers for evaluating clinical response to imrecoxib in OA following ELISA validation. Conclusion This study successfully identified biomarkers for evaluating imrecoxib’s clinical response in patients with OA using 4D-DIA technology. These biomarkers may play a vital role in future personalized OA treatment strategies, pending further confirmation.https://doi.org/10.1007/s40744-023-00636-zOsteoarthritisImrecoxibProteomicsBiomarkers |
| spellingShingle | Han Xie Yuan Zhang Zunyi Zhu Jingxuan Wei Gulinigeer Ainiwaer Weihong Ge Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis Rheumatology and Therapy Osteoarthritis Imrecoxib Proteomics Biomarkers |
| title | Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis |
| title_full | Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis |
| title_fullStr | Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis |
| title_full_unstemmed | Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis |
| title_short | Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis |
| title_sort | plasma proteomic analysis based on 4d dia evaluates the clinical response to imrecoxib in the early treatment of osteoarthritis |
| topic | Osteoarthritis Imrecoxib Proteomics Biomarkers |
| url | https://doi.org/10.1007/s40744-023-00636-z |
| work_keys_str_mv | AT hanxie plasmaproteomicanalysisbasedon4ddiaevaluatestheclinicalresponsetoimrecoxibintheearlytreatmentofosteoarthritis AT yuanzhang plasmaproteomicanalysisbasedon4ddiaevaluatestheclinicalresponsetoimrecoxibintheearlytreatmentofosteoarthritis AT zunyizhu plasmaproteomicanalysisbasedon4ddiaevaluatestheclinicalresponsetoimrecoxibintheearlytreatmentofosteoarthritis AT jingxuanwei plasmaproteomicanalysisbasedon4ddiaevaluatestheclinicalresponsetoimrecoxibintheearlytreatmentofosteoarthritis AT gulinigeerainiwaer plasmaproteomicanalysisbasedon4ddiaevaluatestheclinicalresponsetoimrecoxibintheearlytreatmentofosteoarthritis AT weihongge plasmaproteomicanalysisbasedon4ddiaevaluatestheclinicalresponsetoimrecoxibintheearlytreatmentofosteoarthritis |